ClinicalTrials.gg
CompletedNCT00118755Updated Mar 3, 2011Results posted

A Study of Two Different Schedules of Xeloda (Capecitabine) as First Line Therapy in Patients With Metastatic Colorectal Cancer

A Phase 2 interventional study of capecitabine and Oxaliplatin in Colorectal Cancer, sponsored by Hoffmann-La Roche. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-03-03.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
435
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 179 studies testing capecitabine in Colorectal Neoplasms — 24 open to participants now, 32 under way, 7 of them phase 3. Capecitabine · Colorectal Neoplasms.

Enrollment
17th of 173
435 · median 55
Started
2005
with 10 others
Phase 2
100 of 179
16 open now
Registered
22nd of 179
by date
Lead sponsor
16 of 179
Hoffmann-La Roche

Among the 179 studies testing capecitabine in Colorectal Neoplasms, this one is the 17th largest by enrollment of the 173 interventional ones that give a count, is one of 11 that started in 2005, is one of 100 in phase 2, and was the 22nd registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

24 of the 179 studies testing capecitabine in Colorectal Neoplasms are open now, in 9 countries. Recruiting first, the newest first:

19 more — sign in →

By country, each count listing its studies:

All 24 open studies →

About capecitabine

Capecitabine: first FDA approval 1998 (XELODA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 179 studies testing capecitabine in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This 2-arm study evaluated the efficacy and safety of 2 different treatment schedules of oral Xeloda with intravenous (IV) Eloxatin (oxaliplatin) and IV bevacizumab (Avastin) as a first-line treatment in patients with locally advanced or metastatic colorectal cancer. Patients were randomized to receive either: 1) Xeloda 850 mg/m\^2 orally twice a day (po bid) on Days 1-14, oxaliplatin 130 mg/m\^2 IV on Day 1, and Avastin 7.5 mg/kg IV on Day 1 of each 3-week cycle; or 2) Xeloda 1500 mg/m\^2 po bid on Days 1-7, oxaliplatin 85 mg/m\^2 IV on Day 1 and Avastin 5 mg/kg IV on Day 1 of each 2-week cycle. The anticipated time on study treatment was 1-2 years, and the target sample size was 100-500 individuals.

03

Conditions studied

  • Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or inoperable locally advanced colorectal cancer
  • >=1 measurable target lesion

Exclusion criteria

Exclusion Criteria:

  • Previous systemic therapy for advanced or disease
  • Previous treatment with bevacizumab
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
435 participants (actual)

Study arms

  • Experimental
    1

    Drug: capecitabine · Drug: Oxaliplatin · Drug: bevacizumab

  • Active comparator
    2

    Drug: capecitabine · Drug: Oxaliplatin · Drug: bevacizumab

Interventions

  • 850 mg/m\^2 po bid on Days 1-14 of each 3-week cycle

  • 130 mg/m\^2 IV on Day 1 of each 3-week cycle

  • 7.5 mg/kg IV on Day 1 of each 3-week cycle

  • 1500 mg/m\^2 po bid on Days 1-7 of each 2-week cycle

  • 85 mg/m\^2 IV on Day 1 of each 2-week cycle

  • 5 mg/kg IV on Day 1 of each 2-week cycle

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS)

    Progression-free survival was defined as the time from the date of randomization to the first occurrence of having documented disease progression or death due to any cause, whichever comes first. Progression was based on tumor assessments made by the investigators according to Response Evaluation Criteria in Solid Tumors (RECIST).

    Time frame: Time to disease progression or death (through follow-up phase)

Secondary outcomes

  1. Overall Survival

    Overall survival was defined as the time from the date of randomization to the date of death, for any cause.

    Time frame: Time to death (through follow-up phase): Approximate Median of 718 days

  2. Best Overall Clinical Response

    Overall response rate was assessed according to RECIST (the best response recorded from the time of randomization to the first CR or PR. The patient's overall best response was complete response (CR), partial response (PR) (CR and PR considered "responders"), stable disease (SD), or progressive disease (PD). To be assigned a status of complete response (CR) or partial response (PR), changes in tumor measurements were confirmed by repeat assessments performed no less than 4 weeks after the criteria for response were first met.

    Time frame: Through follow-up phase: Approximate Median of 318 days

  3. Duration of Overall Clinical Response (CR or PR)

    Among tumor responders (i.e., patients with overall best response of CR or PR), duration of overall response was measured from the time criteria were first met for CR or PR (whichever status was recorded first) to the date of either recurrent/progressive disease was objectively documented or death from any cause.

    Time frame: Time to Disease Progression or Death (through follow-up phase): Approximate Median of 302 days

07

Results

Posted Mar 3, 2011

Participant flow

Participant flow — Overall Study
MilestoneXELOX Q3W + BevacizumabXELOX Q2W + Bevacizumab
Started217218
Safety population208211
Completed73
Not completed210215

Outcome measures

PrimaryProgression-free Survival (PFS)

Progression-free survival was defined as the time from the date of randomization to the first occurrence of having documented disease progression or death due to any cause, whichever comes first. Progression was based on tumor assessments made by the investigators according to Response Evaluation Criteria in Solid Tumors (RECIST).

Time frame:
Time to disease progression or death (through follow-up phase)
Reported as:
Median · Days
Progression-free Survival (PFS)
DaysXELOX Q3W + BevacizumabXELOX Q2W + Bevacizumab
Progression-free Survival (PFS)287 (234 to 329)273 (231 to 313)
Statistical analysis
  • XELOX Q3W + Bevacizumab vs XELOX Q2W + Bevacizumab · Log Rank · p = 0.3883 · Hazard ratio (hr): 0.89 · 95% CI 0.67 to 1.17
SecondaryOverall Survival

Overall survival was defined as the time from the date of randomization to the date of death, for any cause.

Time frame:
Time to death (through follow-up phase): Approximate Median of 718 days
Reported as:
Median · Days
Overall Survival
DaysXELOX Q3W + BevacizumabXELOX Q2W + Bevacizumab
Overall Survival852 (605 to 1052)662 (595 to 762)
Statistical analysis
  • XELOX Q3W + Bevacizumab vs XELOX Q2W + Bevacizumab · Log Rank · p = 0.2458 · Hazard ratio (hr): 0.85 · 95% CI 0.64 to 1.12
SecondaryBest Overall Clinical Response

Overall response rate was assessed according to RECIST (the best response recorded from the time of randomization to the first CR or PR. The patient's overall best response was complete response (CR), partial response (PR) (CR and PR considered "responders"), stable disease (SD), or progressive disease (PD). To be assigned a status of complete response (CR) or partial response (PR), changes in tumor measurements were confirmed by repeat assessments performed no less than 4 weeks after the criteria for response were first met.

Time frame:
Through follow-up phase: Approximate Median of 318 days
Reported as:
Number · Patients
Best Overall Clinical Response
PatientsXELOX Q3W + BevacizumabXELOX Q2W + Bevacizumab
Nonresponders (without CR or PR)145167
Responders (with CR or PR)7251
Complete Response (CR)23
Partial Response (PR)7048
Statistical analysis
  • XELOX Q3W + Bevacizumab vs XELOX Q2W + Bevacizumab · Difference in response rate: 9.8 · 95% CI 0.9 to 18.795% Wald asymptotic CI using normal approximation (continuity corrected)
SecondaryDuration of Overall Clinical Response (CR or PR)

Among tumor responders (i.e., patients with overall best response of CR or PR), duration of overall response was measured from the time criteria were first met for CR or PR (whichever status was recorded first) to the date of either recurrent/progressive disease was objectively documented or death from any cause.

Time frame:
Time to Disease Progression or Death (through follow-up phase): Approximate Median of 302 days
Reported as:
Median · Days to event
Duration of Overall Clinical Response (CR or PR)
Days to eventXELOX Q3W + BevacizumabXELOX Q2W + Bevacizumab
Duration of Overall Clinical Response (CR or PR)281 (225 to 397)316 (244 to 522)
Statistical analysis
  • XELOX Q3W + Bevacizumab vs XELOX Q2W + Bevacizumab · Log Rank · p = 0.6294 · Hazard ratio (hr): 1.14 · 95% CI 0.66 to 1.97

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
XELOX Q3W + Bevacizumab—84/208 (40.4%)202/208 (97.1%)
XELOX Q2W + Bevacizumab—94/211 (44.5%)206/211 (97.6%)
Most frequent serious events
Showing 10 of 104
Most frequent serious events
EventXELOX Q3W + BevacizumabXELOX Q2W + Bevacizumab
DiarrhoeaGastrointestinal disorders20/20822/211
DehydrationMetabolism and nutrition disorders21/20818/211
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders8/2083/211
Abdominal PainGastrointestinal disorders3/2086/211
Mucosal InflammationGeneral disorders0/2086/211
Deep Vein ThrombosisVascular disorders5/2082/211
Small Intestinal ObstructionGastrointestinal disorders4/2084/211
VomitingGastrointestinal disorders4/2084/211
Gastrointestinal HaemorrhageGastrointestinal disorders4/2083/211
GastroenteritisInfections and infestations4/2083/211
Most frequent other events
Showing 10 of 47
Most frequent other events
EventXELOX Q3W + BevacizumabXELOX Q2W + Bevacizumab
DiarrhoeaGastrointestinal disorders131/208152/211
NauseaGastrointestinal disorders117/208139/211
FatigueGeneral disorders123/208105/211
Palmar-Plantar Erythrodysaesthesia SyndromeSkin and subcutaneous tissue disorders50/20886/211
VomitingGastrointestinal disorders74/20881/211
Neuropathy PeripheralNervous system disorders67/20857/211
AnorexiaMetabolism and nutrition disorders51/20858/211
Abdominal PainGastrointestinal disorders55/20849/211
Peripheral Sensory NeuropathyNervous system disorders51/20840/211
Weight DecreasedInvestigations31/20845/211

Baseline characteristics

Age Continuous
Age Continuous(years)XELOX Q3W + BevacizumabXELOX Q2W + BevacizumabTotal
Mean60.6 ± 11.4560.8 ± 12.1760.7 ± 11.81
Sex: Female, Male
Sex: Female, Male(Participants)XELOX Q3W + BevacizumabXELOX Q2W + BevacizumabTotal
Female8996185
Male128122250
08

Study locations

No study locations are listed for this record.

09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2005 and a primary completion of Apr 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2011, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2005
First posted
Jul 12, 2005
Start
Jul 2005
Primary completionActual
Apr 2009
Results first posted
Mar 3, 2011
Last update
Mar 3, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00118755
Lead sponsor
Hoffmann-La Roche
First posted
Jul 12, 2005
Start date
Jul 2005
Primary completion
Apr 2009
Results posted
Mar 3, 2011
Last update
Mar 3, 2011

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Capecitabine

Start the discussion